

solianis monitoring ag

Solianis Monitoring AG
Leutschenbachstrasse 46
CH-8050 Zürich
Tel +41 44 306 80 40
Fax +41 44 306 80 41

Media release

Scientific Recognition for Solianis based on Successful Tests

Zurich, February 26, 2009. Recently, Solianis successfully finalized a series of tests during which patients with diabetes have worn its multisensor device for non-invasive glucose monitoring at home and during work in the office. The results of these real-life tests as well as earlier tests in a more controlled environment have driven the decision by Solianis to set up the final device and prepare the market introduction in 2010.

The results of these groundbreaking studies will be presented this year by Dr. Andreas Caduff, Chief Technology Officer to the world-best diabetes experts at the most important international conferences such as the "2nd International ATTD Conference on Advanced Technologies & Treatments for Diabetes (ATTD)" in Athens, the meetings of the „American Diabetes Association“ and the "European Association for the Study of Diabetes".

"Solianis has reached another important milestone with the successful closing of these tests and will now present the status of its technology to an educated audience. This gives Solianis the scientific recognition for almost four years of hard work" says Mario Stark, CEO of Solianis.

Solianis Monitoring AG is a medical devices company developing a non-invasive Continuous Glucose Monitor (CGM) for self-monitoring patients with diabetes. Its technology is based on a unique and proprietary multisensor technology for monitoring physiological parameters. Solianis' non-invasive device delivers comparable results to the minimally invasive devices currently approved by the FDA

Solianis was incorporated in May 2005, and is funded by private investors and the Pioneer Fund of the Cantonal Bank of Zürich. The company plans to introduce its first-generation device for insulin-dependent patients with diabetes by 2010 in Europe, after CE approval. Later product generations will target all patients with diabetes and impaired glucose tolerance.

Contact:

Mario Stark, CEO
Tel: +41 44 306 80 40 / Mob: +41 79 542 88 74
mario.stark@solianis.com / www.solianis.com